Welcome to our dedicated page for Danaher Corporation news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher Corporation stock.
Danaher Corporation (NYSE: DHR) is a globally diversified conglomerate based in Washington, D.C., focusing primarily on life sciences and diagnostics. Founded in 1984 by Stephen and Mitchell Rales, the company has transitioned from a real estate organization into a leading player in the medical, industrial, and commercial products sectors.
Danaher designs, manufactures, and markets a variety of innovative products, particularly scientific instruments and consumables. The company has recently revamped its portfolio by divesting its environmental and applied solutions group, Veralto, in late 2023. This strategic move has allowed Danaher to concentrate its efforts on advancing health through science and technology.
Among Danaher's notable achievements is the acquisition of Abcam plc, which enhances its capabilities in proteomics—an expanding field within life sciences. The company is also known for its contribution to gene-editing therapies through a collaboration with the Innovative Genomics Institute (IGI), aiming to develop CRISPR-based treatments for various diseases.
Danaher's portfolio includes well-known subsidiaries like Beckman Coulter Life Sciences, Integrated DNA Technologies, and Aldevron. These subsidiaries focus on delivering innovative solutions in diagnostics, genomics, and biomanufacturing. For instance, Beckman Coulter's recent partnership with Curiox Biosystems aims to provide automated sample preparation for flow cytometry, enhancing research efficiency.
Financially, Danaher reported better-than-expected revenue in the fourth quarter of 2023, bolstered by strong performance in its life sciences and diagnostics segments. The company's strategic divestitures and acquisitions have positioned it for long-term growth and increased shareholder value.
Danaher’s ongoing projects include a collaboration with Cincinnati Children's Hospital to improve liver organoid technology for drug toxicity screening. This initiative is part of the Danaher Beacons program, which funds pioneering academic research to develop next-generation medical technologies. Another significant collaboration is with Johns Hopkins University, focusing on diagnosing mild traumatic brain injuries (TBI) using advanced biomarker panels.
Overall, Danaher's commitment to scientific excellence, innovation, and continuous improvement makes it a crucial player in advancing healthcare globally. With over 63,000 associates worldwide, Danaher is dedicated to improving quality of life and laying the groundwork for a healthier, more sustainable future.
Danaher Corporation (NYSE: DHR) has priced an offering of $1 billion in 2.800% senior notes due 2051, with an offering price set at 99.396% of the principal amount. The expected net proceeds are approximately $984 million, intended for redeeming all outstanding 2.500% senior notes due 2025, refinancing debt, working capital, and other corporate purposes. The offering is anticipated to close on December 10, 2021, subject to customary conditions. This move is part of Danaher's strategy to manage its debt efficiently.
IDBS, a Danaher operating company, launched Polar Insight, enhancing its BioPharma Lifecycle Management (BPLM) platform with advanced data analytics and visualization tools. This innovation replaces outdated manual processes, allowing for integrated digital workflows that streamline data handling from development to manufacturing. The new capabilities aim to accelerate innovation and regulatory filings, enabling clients to deliver vaccines and therapies more efficiently. The first dashboards will be available in Q1 2022.
Danaher Corporation (NYSE:DHR) will redeem €800,000,000 of 2.500% Senior Notes due 2025. The redemption price includes the principal amount, a make-whole premium, and accrued interest. This action will occur on December 29, 2021. Danaher is a global technology innovator in health care and environmental markets, committed to solving complex challenges. With over 69,000 associates, the company maintains a strong operational culture based on the Danaher Business System.
Danaher Corporation (NYSE: DHR) will have its President and CEO, Rainer M. Blair, present at the Evercore ISI HealthCONx Conference on December 1, 2021, at 1:00 p.m. ET. The presentation will be webcast live on www.danaher.com. Danaher is a leader in science and technology, dedicated to solving complex challenges in health care, environmental, and applied markets, with around 69,000 associates globally. For further details, visit their website.
Danaher Corporation (NYSE: DHR) reported strong third-quarter results for 2021, achieving net earnings of $1.2 billion or $1.54 per diluted share, marking a 33% YoY increase. Revenues surged 23% YoY to $7.2 billion, with non-GAAP core revenue growth of 20.5%. The company also noted significant increases in operating cash flow and free cash flow, up 51% and 46.5% YoY, respectively. Looking ahead, Danaher expects non-GAAP core revenue growth in the low-to-mid teens for Q4 and over 20% for the full year 2021. The recent acquisition of Aldevron is set to bolster its genomic medicine capabilities.
Beckman Coulter has launched the DxU Iris Workcell, an automated urinalysis system, at the AACC Annual Scientific Meeting on September 28, 2021. This innovative system reduces manual reviews to 4% and minimizes workflow disruptions in laboratories. The DxU Iris Workcell integrates advanced technology for enhanced accuracy and standardization in urinalysis, addressing increased laboratory demands, especially post-pandemic. It features a Load and Unload station for managing 190 samples and is designed for high-volume laboratories, promoting faster turnaround times and improved laboratory efficiency.
Danaher Corporation (NYSE: DHR) will host its third quarter 2021 earnings conference call on October 21, 2021, at 8:00 a.m. ET. The call will last about one hour and will be available via webcast on Danaher's website. A replay will follow shortly after and remain accessible until November 4, 2021. The earnings press release and presentation materials will be posted at 6:00 a.m. ET on the same day.
Danaher focuses on science and technology solutions, impacting healthcare and environmental sectors with over 69,000 associates.
Danaher Corporation (NYSE: DHR) has declared a quarterly cash dividend of $0.21 per share on common stock, payable on October 29, 2021, to record holders as of September 30, 2021. Additionally, the company announced dividends for its Series A and Series B Mandatory Convertible Preferred Stock: $11.875 and $12.50 per share, respectively, both payable on October 15, 2021, to holders of record on September 30, 2021.
SCIEX has launched the BioPhase 8800 system, a groundbreaking capillary electrophoresis solution enabling simultaneous processing of eight samples. This innovation addresses the growing complexities in biopharmaceutical development, enhancing the speed and accuracy of analyses critical for next-gen drug development. Key features include high throughput, integrated detection modules, and user-friendly software, promising to shorten analysis time from one month to just one week. As part of Danaher (NYSE: DHR), SCIEX continues to lead in solutions that enhance bioprocessing efficiency.
FAQ
What is the current stock price of Danaher Corporation (DHR)?
What is the market cap of Danaher Corporation (DHR)?
What does Danaher Corporation specialize in?
Who founded Danaher Corporation and when?
Where is Danaher Corporation headquartered?
What recent divestiture has Danaher Corporation made?
What are some of Danaher's notable subsidiaries?
What recent acquisition has enhanced Danaher's capabilities in proteomics?
What is the Danaher Beacons program?
What collaboration is Danaher involved in to improve liver organoid technology?
What is the focus of Danaher's partnership with Johns Hopkins University?
How does Danaher contribute to the field of gene-editing therapies?
